• Article

Budget impact of adding peginterferon beta-1A to the formulary for the treatment of relapsing forms of multiple sclerosis

Bibliography

Mauskopf, J., Graham, J., Fay-Azhar, M., & Kinter, E. (2015). Budget impact of adding peginterferon beta-1A to the formulary for the treatment of relapsing forms of multiple sclerosis. Value in Health, 18(3), A280-A281. DOI: 10.1016/j.jval.2015.03.1638

To estimate the budget impact of adding peginterferon beta-1a, a new interferon requiring injections only every two weeks for the treatment of relapsing forms of multiple sclerosis (MS), to a managed care formulary in the US.